BBK Healthcare, Inc. Evolves to Become BBK Worldwide
BBK Adds Global Alliances and Restructures Offerings to Advance Patient Recruitment.
BOSTON-BBK Healthcare, Inc., a leading patient recruitment company for the clinical R&D segment of the pharmaceutical, biotechnology, and medical device industries announces the evolution of its global capabilities and presence to become BBK Worldwide. The company is leveraging its 20-year industry experience in patient recruitment planning and implementation in North America with wider global coverage and a strategic restructuring of offerings to respond to the increasingly complex needs of clinical research sponsors entering new and emerging global markets.
BBK Worldwide's official launch coincides with the Drug Information Association (DIA) Annual Meeting in Philadelphia from June 18–22, where BBK will convene global alliance members for an inaugural summit meeting prior to the DIA conference.
Geographic expansion includes BBK Worldwide offices in London and Prague, and the addition of the BBK Worldwide Alliance, a network of select, best-in-class companies with capabilities in more than 75 countries.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
